Introduction
============

Type 2 diabetes (T2D), characterized by an inadequate β-cell response to progressive insulin resistance, is a highly prevalent disease affecting \~9% of the global population, and is fast-becoming a worldwide epidemic ([@b1-mmr-17-06-7636],[@b2-mmr-17-06-7636]). The clinical symptoms of T2D include hyperglycemia, obesity, hypertension and hyperlipidemia. Furthermore, T2D may induce disease-specific complications, including blindness, renal failure and increased risk of cardiovascular disease, which may result in a reduced quality of life and an increased mortality rate of patients with T2D ([@b3-mmr-17-06-7636],[@b4-mmr-17-06-7636]).

T2D is a complex disease that may be attributed to the interplay between environmental and genetic risk factors ([@b5-mmr-17-06-7636]). Poor diets and sedentary lifestyles are prominent environmental contributors leading to the development of T2D ([@b6-mmr-17-06-7636]). Epigenetic factors have been revealed to be heavily implicated in the complex interplay between environmental signals and intrinsic genetic alterations ([@b7-mmr-17-06-7636]). DNA methylation is an epigenetic modification most commonly associated with cysteine-phosphate-guanine (CpG) sites situated within the promoter region, and degrees of organismal DNA methylation are changeable depending on environmental factors. Furthermore, DNA methylation may modulate gene expression without altering the sequence of DNA via suppression of DNA transcription or modification of the surrounding chromatin. Methylation may suppress transcription by modulating the binding of transcription factors (TFs) to DNA, and via recruitment of methyl binding proteins and transcriptional corepressors ([@b8-mmr-17-06-7636]). Therefore, DNA methylation modification represents a link between environmental risk factors and disease progression by influencing gene transcription patterns and, subsequently, organ function. Typically, advancing age, physical inactivity, weight gain and obesity are primary risk factors for the development of T2D ([@b9-mmr-17-06-7636]). In addition, patients suffering from metabolic syndromes with inherent symptoms of glucose intolerance, insulin resistance and abdominal obesity are considered to be in prediabetic state, which may ultimately develop into T2D ([@b10-mmr-17-06-7636]). Previous studies have revealed an association between DNA methylation patterns and alterations in body weight and physical activity. Furthermore, CpG markers of DNA methylation are biomarkers for metabolic syndrome ([@b11-mmr-17-06-7636]--[@b13-mmr-17-06-7636]). Alterations in metabolite levels, including choline, betaine and methionine, are implicated in methylation pathways in the liver ([@b14-mmr-17-06-7636],[@b15-mmr-17-06-7636]), and choline-associated metabolites have been demonstrated to be implicated in the pathological development of T2D ([@b16-mmr-17-06-7636]). Therefore, DNA methylation has been hypothesized to have an involvement in the pathogenesis of T2D. Furthermore, the negative correlation between increased methylation levels of β-cell specific genes, including pancreatic and duodenal homeobox1 and insulin, and the expression levels of their corresponding proteins, have previously been detected in the pancreatic islets of patients with T2D ([@b17-mmr-17-06-7636],[@b18-mmr-17-06-7636]). Therefore, there is an incentive to investigate the potential implications of DNA methylation and the associated gene expression pattern modifications with regards to the pathogenic onset of T2D.

T2D is a highly complex multisystem disease. Reduced rates of muscular glycogen synthesis in patients with insulin-dependent diabetes may be induced by defective glucose transport/phosphorylation ([@b19-mmr-17-06-7636]). Furthermore, alterations in mitochondrial gene transcription patterns in skeletal muscle are closely associated with insulin-dependent T2D ([@b20-mmr-17-06-7636]). In addition, the liver is implicated in the regulation of lipid and glucose metabolism, disorders of which frequently occur in non-alcoholic fatty liver disease (NAFLD) and T2D ([@b21-mmr-17-06-7636]). In the present study, a systematic analysis was performed using publicly-available online genome-wide methylome and transcriptome data from liver tissues from age-matched healthy and obese T2D men, uploaded by Kirchner *et al* ([@b22-mmr-17-06-7636]), in order to identify disease-associated genes and to better understand T2D at the molecular level. Unlike the study by Kirchner *et al* ([@b22-mmr-17-06-7636]), the present study aimed to reveal the protein-protein interaction (PPI), TF target and microRNA (miRNA) target networks among the differentially-expressed genes (DEGs), in order to develop a more comprehensive understanding of protein function associated with T2D.

Materials and methods
=====================

### Microarray data

The raw data on gene expression were downloaded from the Gene Expression Omnibus (GEO) database ([www.ncbi.nlm.nih.gov/geo](www.ncbi.nlm.nih.gov/geo)), accession no. GSE64998. This dataset, including 21 samples (liver biopsies from six non-obese, eight obese non-diabetic and seven obese T2D men), were collected based on the GPL11532 platform (HuGene-1_1-st) Affymetrix Human Gene 1.1 ST Array \[transcript (gene) version\]. The data on liver tissues isolated from six non-obese men and seven obese T2D men were extracted. These data were uploaded by Kirchner *et al* ([@b22-mmr-17-06-7636]); their study was conducted according to the principles described in the Declaration of Helsinki, the regional ethics committee at the Karolinska Insitute (Solna, Sweden) approved the study, and all participants provided informed written consent.

Furthermore, the methylation profile data based on the GPL13534 platform \[Illumina Human Methylation 450 BeadChip (HumanMethylation450_15017482)\] were downloaded from the GEO database, accession no. GSE65057. The data on liver tissues isolated from seven non-obese controls and nine obese T2D samples were extracted from GSE65057, which were uploaded by Kirchner *et al* ([@b22-mmr-17-06-7636]).

### Data preprocessing

Raw expression profile data in the CEL format were preprocessed using the Oligo package in R ([@b23-mmr-17-06-7636]), which included format transition, missing value interpolation, background correction and data quantile normalization.

The RnBeads Package ([@b24-mmr-17-06-7636]), which used β-values in order to characterize the degree of DNA methylation, was applied for analysis of the downloaded methylation microarray data. Initially, the Infinium probes were manipulated using the Methylumi package ([@b25-mmr-17-06-7636]). Following this, background correction was performed with the normal-exponential convolution using the out-of-band probes method ([@b26-mmr-17-06-7636]), and normalization was performed using the Beta MIxture Quantile dilation method ([@b27-mmr-17-06-7636]). Finally, the probes with a detection value of P\>0.01 or bead count \<3, located on sex chromosomes or in regions enriched with single nucleotide polymorphisms, were deleted ([@b28-mmr-17-06-7636]).

### DEG and differentially-methylated gene (DMG) screening

The empirical Bayes approach in the Limma package ([@b29-mmr-17-06-7636]) was used in order to identify differing levels of DEGs and DMGs between the healthy controls and the obese T2D samples. DEGs were classified as those meeting the criteria of P\<0.05 and \|log fold change\|≥0.5, and DMGs were those with P\<0.05. Furthermore, DMGs were mapped to the DEGs in order to identify any overlaps.

### Functional and pathway enrichment analyses

The Multifaceted Analysis Tool for Human Transcriptome ([www.biocloudservice.com](www.biocloudservice.com)) online tool in BioCloud, a platform storing vast amounts of bioinformatics data and providing analysis software applications, was used to perform Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway and Gene Ontology (GO) functional enrichment analyses for the upregulated genes, the downregulated genes and the overlapping genes. KEGG and GO are freely available for public use for the annotation of genes, gene products and gene sequences ([@b30-mmr-17-06-7636],[@b31-mmr-17-06-7636]). P\<0.05 was set as the threshold criterion.

### Construction of PPI network

The PPIs among the DEGs were analyzed using the STRING database ([@b32-mmr-17-06-7636]) and the default parameters, and the combined score \>0.4 was set as the threshold. Following this, Cytoscape software v3.2.0 ([@b33-mmr-17-06-7636]) was used in order to visualize the PPI network, and connectivity degree analysis was performed in order to screen for hub genes ([@b34-mmr-17-06-7636]). Furthermore, the sub-network involving overlapping genes was extracted from the PPI network.

### Construction of the regulatory network for overlapping genes involved in the sub-network

Using the iRegulon plugin ([@b35-mmr-17-06-7636]) in Cytoscape software ([@b33-mmr-17-06-7636]), the TFs targeting the overlapping genes involved in the sub-network were predicted. TF target pairs with a normalized enrichment score \>4, calculated with iRegulon plugin, were selected, and the TF target regulatory network was constructed using Cytoscape software ([@b33-mmr-17-06-7636]). In addition, miRNAs targeting the overlapping genes involved in the sub-network were predicted using the WebGestalt tool ([@b36-mmr-17-06-7636],[@b37-mmr-17-06-7636]). Following the determination of the miRNA target pairs, the miRNA target regulatory network was visualized using Cytoscape software ([@b33-mmr-17-06-7636]).

### Data validation of DEGs

A further GSE15653 dataset was used for validation of the DEGs already identified. The GSE15653 dataset was downloaded from GEO, and included four liver tissue samples from obese T2D patients and five healthy controls. Following this, the raw expression profile data in the CEL format from the GSE15653 dataset were preprocessed using the same methods above, and the DEGs in the obese T2D samples were also identified also using the same methods and threshold value used above. Subsequently, the shared upregulated and downregulated DEGs in the GSE15653 and GSE64998 datasets were obtained via Venn analysis, and these identified DEGs were considered to validate the genes identified from GSE64998 dataset.

Results
=======

### Identification of DEGs and DMGs

Following analysis of the gene expression profiles of the non-obese and the obese T2D samples, 251 DEGs were detected, including 124 upregulated genes and 127 downregulated genes. Furthermore, 9,698 DMGs (6,021 upregulated genes and 3,677 downregulated genes) were identified in obese diabetic individuals compared with non-obese controls (P\<0.05). Following the mapping of the DEGs to the DMGs, a total of 103 overlapping genes were revealed (47 upregulated genes and 56 downregulated genes) in the gene expression profiles.

### Functional and pathway enrichment analyses

In order to examine the biological functions of abnormal genes in obesity-associated T2D, GO and KEGG enrichment analyses were performed using the previously identified DEGs and the overlapping genes. [Fig. 1A and B](#f1-mmr-17-06-7636){ref-type="fig"} present the enriched KEGG pathways for the downregulated genes and upregulated genes, respectively; and [Fig. 1C and D](#f1-mmr-17-06-7636){ref-type="fig"} present the top five prevalent GO terms for the downregulated genes and upregulated genes, respectively. The upregulated genes were most significantly enriched in 'biosynthesis of unsaturated fatty acids' (KEGG pathway; P=9.46×10^−4^), and the downregulated genes were significantly enriched in KEGG pathways including 'nitrogen metabolism' (P=3.52×10^−4^) and 'cysteine and methionine metabolism' (P=2.89×10^−2^). Furthermore, the 103 overlapping genes were significantly enriched in 'arginine and proline metabolism' (KEGG pathway; P=5.53×10^−3^) and 'oxidation-reduction reactivity' (GO term; P=3.52×10^−4^; [Table I](#tI-mmr-17-06-7636){ref-type="table"}).

### Construction of PPI network

PPIs were determined by STRING database analysis, and a PPI network with 116 nodes and 189 edges was generated for the DEGs ([Fig. 2](#f2-mmr-17-06-7636){ref-type="fig"}). The top 20 nodes with the highest degrees are detailed in [Table II](#tII-mmr-17-06-7636){ref-type="table"}. Notably, fatty acid synthase (*FASN*), cyclin D1 (*CCND1*), glucokinase (*GCK*), stearoyl-CoA desaturase (*SCD*), and PPARG coactivator α (*PPARGC1A*) were all overlapping genes in the PPI network.

Furthermore, KEGG pathway and GO functional enrichment analyses revealed that the top 20 nodes were predominantly associated with cancer pathways, including 'p53 signaling pathway' (KEGG pathway; P=1.36×10^−3^), and 'regeneration' (GO term, P=1.80×10^−6^; [Table III](#tIII-mmr-17-06-7636){ref-type="table"}).

### Construction of TF target network and miRNA target network

TFs and miRNAs are able to regulate gene expression via modulation of transcriptional activation and stability of mRNA, respectively ([@b38-mmr-17-06-7636]). In the present study, the TF target and miRNA target pairs were predicted based on the overlapping genes involved in the sub-network in order to explore their potential regulatory relationships. A total of 10 TFs were predicted and the TF target network contained 49 nodes and 161 pairs ([Fig. 3](#f3-mmr-17-06-7636){ref-type="fig"}). The hub genes with the highest degrees are detailed in [Table IV](#tIV-mmr-17-06-7636){ref-type="table"}. A total of 49 miRNAs, which may be implicated in the abnormal expression of the overlapping genes, were predicted. Following this, a miRNA target network, including 87 nodes and 180 regulatory relationships, was constructed ([Fig. 4](#f4-mmr-17-06-7636){ref-type="fig"}). Furthermore, the hub genes with the highest degrees were screened for ([Table V](#tV-mmr-17-06-7636){ref-type="table"}).

### Validation of the expression levels of DEGs

A total of 753 upregulated DEGs and 432 downregulated DEGs were identified from the GSE15653 validation dataset using the obesity-associated T2D patients and control samples according to the same method used to identify DEGs in the GSE64998 dataset. By comparing the datasets, it was revealed that among the 124 upregulated DEGs in GSE64998, 15 genes were overlapping genes (e.g., *CCND1* and *FASN*), while among the 127 downregulated DEGs, 20 overlapping genes \[e.g., tyrosine immunotransferase (*TAT*)\] were searched. Overlapping DEGs between both datasets were considered to represent preliminary verification of said genes in the GSE64998 dataset ([Table VI](#tVI-mmr-17-06-7636){ref-type="table"}).

Discussion
==========

The high prevalence of T2D and the severity of its associated complications raise great challenges for effective disease management ([@b39-mmr-17-06-7636]). In China, obesity is one of the principal contributory risk factors for T2D development ([@b9-mmr-17-06-7636]). Despite several genes and their regulatory mechanisms being suggested to be implicated in the development of obesity-associated T2D, there remains a requirement for further research in order to uncover the underlying molecular mechanisms implicated in T2D pathogenesis. In the present study, systematic analysis using gene expression patterns and DNA methylation profiles of healthy controls and obese T2D patients was performed in order to reveal hub genes, which may be involved in the pathogenesis of obesity-associated T2D. By performing PPI, TF target and miRNA network analyses, the present study demonstrated that the hub nodes *CCND1, PPARGC1A*, ATP citrate lyase (*ACLY*), *TAT* and *FASN* may be implicated in the development of obesity-associated T2D.

*CCND1* encodes the cyclin D1 protein, and expression of *CCND1* has marked periodicity throughout the cell cycle ([@b40-mmr-17-06-7636]). Previous studies have demonstrated an association between the dysregulation of *CCND1* expression and T2D ([@b41-mmr-17-06-7636]--[@b43-mmr-17-06-7636]). Microarray and reverse transcription-quantitative polymerase chain reaction data have previously revealed a higher expression pattern of *CCND1* in diabetic islets compared with healthy controls ([@b43-mmr-17-06-7636]). In accordance with this, the present study predicted from the GSE64998 and GSE15653 datasets that the expression of *CCND1* was upregulated in patients with T2D. In addition, the increased methylation of *CCND1* was detectable in patients with T2D ([@b44-mmr-17-06-7636]). However, it has previously been reported that there is no association between the methylation status of *CCND1* and its expression ([@b45-mmr-17-06-7636]). Further studies are required to reveal how *CCND1* is implicated in T2D pathogenesis.

*PPARGC1A* is a transcriptional coactivator that modulates genes associated with energy metabolism ([@b46-mmr-17-06-7636]). Numerous studies have demonstrated the link between *PPARGC1A*, and the development of T2D and associated insulin resistance. Decreased *PPARGC1A* expression has been detected in cases of insulin resistance ([@b47-mmr-17-06-7636]--[@b49-mmr-17-06-7636]). Furthermore, increased DNA methylation at the site of the *PPARGC1A* promoter has been detected in skeletal muscle tissue and in the islets of patients with T2D ([@b50-mmr-17-06-7636]). In addition, a negative correlation between the methylation of *PPARGC1A* and its expression has previously been reported ([@b51-mmr-17-06-7636]). In line with these previous findings, abnormal expression and methylation of *PPARGC1A* was demonstrated in liver tissues from obese T2D patients in the present study.

In the present study, it was revealed that DNA methylation corresponds with the upregulation of *ACLY, FASN, SCD* and *GCK* expression in samples from obese patients with T2D, and had high degrees in the PPI network. *ACLY, FASN, GCK* and *SCD* are all enzymes implicated in metabolic processes. *ACLY* is implicated in the synthesis of cytosolic acetyl-coenzyme (Co)A in numerous tissue types ([@b52-mmr-17-06-7636]). Furthermore, Guay *et al* ([@b53-mmr-17-06-7636]) demonstrated that *ACLY* is a fundamental regulator of glucose-induced insulin secretion. *FASN*, coding for fatty acid synthase, catalyzes the synthesis of palmitate from acetyl-CoA and malonyl-CoA, producing long-chain saturated free fatty acids in the presence of nicotinamide adenine dinucleotide phosphate. Genetic alterations affecting *FASN* activity may be significantly correlated with T2D via modification of insulin sensitivity ([@b54-mmr-17-06-7636]). A further interpretation of the association of *FASN* with T2D is that an increase in fatty acids may inhibit insulin signaling and induce metabolic insulin resistance in patients with T2D ([@b55-mmr-17-06-7636]). Furthermore, it has previously been suggested that methylation of the *FASN* promoter at the 611, 096, 61780, 61778 and 61774 CpG sites may be associated with the progression of NAFLD ([@b56-mmr-17-06-7636]), which is associated with an increased risk of T2D. *SCD* encodes for the stearoyl-CoA desaturase enzyme that is responsible for fatty acid biosynthesis, which is implicated in lipid-induced insulin resistance, and *SCD* deficiency increases insulin signaling ([@b57-mmr-17-06-7636]), Furthermore, the expression of *SCD* is upregulated in diabetic fatty rats ([@b58-mmr-17-06-7636]). In addition, it has been suggested that alterations in *SCD* expression as a consequence of DNA promoter methylation in morbidly obese patients are associated with the serum levels of free fatty acids ([@b59-mmr-17-06-7636]). Furthermore, the levels of mRNA encoding *ACLY, FASN* and *SCD* were markedly upregulated in the livers of Zucker fatty rats, which are commonly used as animal models for fatty liver disease, hepatic insulin resistance and obesity investigations ([@b60-mmr-17-06-7636]). Functional enrichment analysis in the present study revealed that abnormal *FASN* and *SCD* expression levels in obesity-associated T2D were predominantly associated with fatty acid biosynthesis metabolism and oxidation reduction. *GCK* is responsible for the phosphorylation of glucose in order to produce glucose-6-phosphate, which is the first step in the majority of glucose metabolic pathways ([@b61-mmr-17-06-7636]). *GCK* is predominantly expressed in pancreatic β cells and hepatocytes, and it is implicated the modulation of glucose homeostasis in liver, including glucose synthesis, breakdown and storage ([@b62-mmr-17-06-7636]). It has previously been demonstrated that fluctuations in the expression levels of *GCK* are a risk factor for the development of T2D ([@b63-mmr-17-06-7636]). Furthermore, elevated levels of CpG island methylation within the *GCK* gene have been reported in patients with T2D ([@b64-mmr-17-06-7636]). Therefore, the upregulation of *ACLY, FASN, SCD* and *GCK* gene expression levels, accompanied by alterations in DNA methylation levels, may be implicated in the development of obesity-associated T2D via regulation of fatty acid and glucose metabolic pathways, and involvement in oxidoreductive and insulin signaling pathways.

The downregulated genes identified in patients with T2D were significantly enriched in the cysteine and methionine metabolic pathways. A previous study reported that cysteine and methionine intake has an association with T2D ([@b65-mmr-17-06-7636]), and that levels of oxidation at cysteine and methionine residues are markedly higher in patients with diabetes compared with nondiabetic individuals ([@b66-mmr-17-06-7636]). The present study revealed that the downregulation of cystathionine γ lyase (*CTH*) and *TAT* genes is associated with the metabolism of cysteine and methionine in patients with T2D. Furthermore, a deficiency in *CTH* may impair H~2~S biosynthesis and vessel reactivity in T2D ([@b67-mmr-17-06-7636]). *TAT* is present in the liver and catalyzes the conversion of L-tyrosine into phosphorylated hydroxyphenylpyruvate, and its expression is abnormal in diabetic rats ([@b68-mmr-17-06-7636]). Thus, we hypothesized that the downregulated expression of *CTH* and *TAT* altered the DNA methylation levels in obese patients with T2D. However, the influence of their methylation status on the development of T2D has yet to be determined. Further research is required in order to determine whether the alteration in DNA methylation levels in *CTH* and *TAT* is correlated with their downregulated expression in T2D.

However, although the present study identified genes with altered expression and DNA methylation in T2D by reanalyzing a published dataset, a number of novel genes were demonstrated to serve potential roles in T2D. These results prove beneficial to the development of a deeper understanding of obesity-associated T2D disease progression. However, the present study had certain limitations. The sample sizes analyzed in GSE64998 and GSE65057 datasets were small. In addition, the association between the expression levels of the DEGs and patterns of DNA methylation were not investigated. Future studies may investigate the correlation between the DEGs and DMGs, and analyze the methylation sites in such DEGs using large sample sizes.

In conclusion, the present study analyzed the mRNA expression and DNA methylation profiles of healthy controls and of patients with obesity-associated T2D using a computational bioinformatics approach. Genes with abnormal expression levels were screened for and the biological functions enriched by these genes were explored. In the present study, several key genes (*ACLY, CCND1, PPARGC1A, FASN, GCK, SCD, CTH* and *TAT*) were revealed to be potentially implicated in the progression of insulin resistance in obesity and T2D. However, further experimental studies are required in order to validate the implications of these genes in obesity-associated T2D.

The present study was supported by the Overseas Study Project of Jiangsu Province for Outstanding Young and Middle-aged Teachers and Principals of Colleges and Universities (grant no. Jiangsu Teachers 2012-13).
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###### 

KEGG pathways and the top 10 GO BP terms enriched by the overlapping genes.

  A, Pathway                                                                                               
  --------------------------- -------------------------------------------------- ----------- ------------- ---------------------------------------------------------------------------------------------------
  **hsa00330**                Arginine and proline metabolism                    4           5.53×10^−3^   *GLS2, ALDH18A1, OAT, PRODH*
                                                                                                           
  **B, Biological process**                                                                                
                                                                                                           
  **ID**                      **Name**                                           **Count**   **P-value**   **Genes**
                                                                                                           
  **GO:0016053**              Organic acid biosynthetic process                  7           3.07×10^−4^   *ALDH18A1, SDS, SCD, ELOVL2, FASN, LGSN, PRODH*
  **GO:0046394**              Carboxylic acid biosynthetic process               7           3.07×10^−4^   *ALDH18A1, SDS, SCD, ELOVL2, FASN, PRODH*
  **GO:0055114**              Oxidation reduction                                13          3.52×10^−4^   *ME1, HSD17B11, TP53I3, ALDH18A1, FMO1, SCD, CYP4F22, FASN, AASS, CYP26A1, PPARGC1A, HPGD, PRODH*
  **GO:0009064**              Glutamine family amino acid metabolic process      4           3.57×10^−3^   *GLS2, ALDH18A1, LGSN, PRODH*
  **GO:0006739**              NADP metabolic process                             3           3.93×10^−3^   *ME1, TP53I3, GCK*
  **GO:0009084**              Glutamine family amino acid biosynthetic process   3           5.53×10^−3^   *ALDH18A1, LGSN, PRODH*
  **GO:0033273**              Response to vitamin                                4           6.97×10^−3^   *CCND1, PDGFA, IGFBP2, SPP1*
  **GO:0007156**              Homophilic cell adhesion                           5           7.53×10^−3^   *RET, CDH15, FAT1, DSG1, CDH23*
  **GO:0007155**              Cell adhesion                                      11          8.04×10^−3^   *RET, CDH15, EPDR1, LAMA5, FAT1, DSG1, CPXM2, IL32, CYR61, SPP1, CDH23*
  **GO:0022610**              Biological adhsion                                 11          8.12×10^−3^   *RET, CDH15, EPDR1, LAMA5, FAT1, DSG1, CPXM2, IL32, CYR61, SPP1, CDH23*

KEGG, Kyoto Encyclopedia of Genes and Genomes; GO, Gene Ontology; BP, biological process.

###### 

Top 20 genes with higher degrees in the protein-protein interaction network.

  Genes        Degree
  ------------ --------
  *ACLY*       19
  *FASN*       15
  *CCND1*      13
  *GCK*        12
  *SCD*        12
  *MET*        12
  *IGF1*       12
  *ALDH18A1*   11
  *SERPINE1*   9
  *FDFT1*      8
  *SQLE*       8
  *TAT*        7
  *HSPA5*      7
  *IGFBP1*     7
  *CDKN1A*     7
  *C10orf10*   6
  *SDS*        6
  *SPP1*       6
  *FABP4*      6
  *PPARGC1A*   6

###### 

KEGG pathways and GO BP terms enriched for the top 20 nodes in the protein-protein interaction network.

  A, Pathway                                                                                                             
  --------------------------- ---------------------------------------------------------------- ----------- ------------- ------------------------------------------------------
  **hsa04115**                p53 signaling pathway                                            4           1.36×10^−4^   *CDKN1A, CCND1, SERPINE1, IGF1*
  **hsa05218**                Melanoma                                                         4           1.54×10^−3^   *CDKN1A, CCND1, MET, IGF1*
  **hsa05214**                Glioma                                                           3           1.82×10^−2^   *CDKN1A, CCND1, IGF1*
  **hsa04510**                Focal adhesion                                                   4           2.75×10^−2^   *CCND1, MET, IGF1, SPP1*
  **hsa05215**                Prostate cancer                                                  3           3.47×10^−2^   *CDKN1A, CCND1, IGF1*
                                                                                                                         
  **B, Biological process**                                                                                              
                                                                                                                         
  **Pathway ID**              **Pathway name**                                                 **Count**   **P-value**   **Genes**
                                                                                                                         
  **GO:0031099**              Regeneration                                                     5           1.80×10^−6^   *CDKN1A, CCND1, SERPINE1, IGF1, IGFBP1*
  **GO:0010033**              Response to organic substance                                    8           2.25×10^−5^   *CDKN1A, CCND1, GCK, SQLE, FABP4, IGFBP1, TAT, SPP1*
  **GO:0009725**              Response to hormone stimulus                                     6           9.15×10^−5^   *CDKN1A, CCND1, FABP4, IGFBP1, TAT, SPP1*
  **GO:0048545**              Response to steroid hormone stimulus                             5           1.03×10^−4^   *CDKN1A, CCND1, FABP4, TAT, SPP1*
  **GO:0051384**              Response to glucocorticoid stimulus                              4           1.41×10^−4^   *CDKN1A, CCND1, FABP4, TAT*
  **GO:0009719**              Response to endogenous stimulus                                  6           1.46×10^−4^   *CDKN1A, CCND1, FABP4, IGFBP1, TAT, SPP1*
  **GO:0009991**              Response to extracellular stimulus                               5           1.74×10^−4^   *CDKN1A, CCND1, HSPA5, PPARGC1A, SPP1*
  **GO:0031960**              Response to corticosteroid stimulus                              4           1.82×10^−4^   *CDKN1A, CCND1, FABP4, TAT*
  **GO:0010907**              Positive regulation of glucose metabolic process                 3           2.82×10^−4^   *GCK, IGF1, PPARGC1A*
  **GO:0010676**              Positive regulation of cellular carbohydrate metabolic process   3           3.13×10^−4^   *GCK, IGF1, PPARGC1A*

KEGG, Kyoto Encyclopedia of Genes and Genomes; GO, Gene Ontology.

###### 

Top 12 genes with higher degrees in the transcriptional factor-target regulatory network.

  Genes        Degree
  ------------ --------
  *CCND1*      15
  *PPARGC1A*   11
  *WNT11*      11
  *ZSCAN16*    10
  *PRKCE*      9
  *SULF1*      9
  *GCK*        8
  *RET*        8
  *SLITRK3*    8
  *OAT*        7
  *SCD*        7
  *ME1*        7

###### 

Top 14 genes with higher degrees in the microRNA target regulatory network.

  Genes        Degree
  ------------ --------
  *TP53INP1*   15
  *SLC1A2*     13
  *PPARGC1A*   12
  *SLITRK3*    11
  *L3MBTL3*    11
  *RET*        10
  *CCND1*      8
  *RBMS1*      7
  *GRID1*      7
  *PSD3*       7
  *PRKCE*      6
  *ANKS1B*     5
  *SULF1*      5
  *HMCN1*      5

###### 

Overlapped genes between the GSE64998 dataset and GSE15653 validation dataset.

  Common upregulated genes                                                                                                                      Common downregulated genes
  --------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------
  *RDH16, SLC39A7, KRT8, AEN, HSPA5, KDM8, ALDH18A1, ATF5, CDHR2, CCND1, SLC35C1, CD151, GAS6, ACOT1, HPS5, APOL3, FASN, CHI3L1, CDKN1A, HBB*   *SLITRK3, CYP2C19, SLC16A4, CA14, GPR88, OPN3, VIL1, HAL, HERC5, DNAJC12, TAT, PFKFB3, SMPDL3A, SLC19A2, ABCA8*

[^1]: Contributed equally
